1 Result: Ipsen
Momentum Surge: Elafibranor's PBC Trial Data Boosts Genfit
June 30th, 2023
Ipsen S.A. (OTCMKTS: IPSEY) and Genfit S.A. (Nasdaq: GNFT) have announced positive results from the ELATIVE Phase III trial evaluating elafibranor as a treatment for patients with primary biliary cholangitis (PBC), a rare cholestatic liver disease, w. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
Treasury Targets Global Scam Networks and the Corporate Infrastructure That Enables Them
November 06th, 2026FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
November 05th, 2026New Details Emerge in Amazon Ads Auction-Rigging Case
November 05th, 2026November 02nd, 2026
Member Login